LSV Asset Management Sells 28,547 Shares of Solventum Corporation $SOLV

LSV Asset Management trimmed its position in shares of Solventum Corporation (NYSE:SOLV) by 81.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 6,575 shares of the company’s stock after selling 28,547 shares during the quarter. LSV Asset Management’s holdings in Solventum were worth $521,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Assetmark Inc. grew its stake in shares of Solventum by 21.4% during the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares during the last quarter. Hilltop National Bank grew its stake in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the last quarter. Allworth Financial LP grew its stake in shares of Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after purchasing an additional 129 shares during the last quarter. CIBC Private Wealth Group LLC grew its stake in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after purchasing an additional 134 shares during the last quarter. Finally, BOKF NA grew its stake in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after purchasing an additional 141 shares during the last quarter.

Insider Activity at Solventum

In related news, Director Amy Mcbride Wendell acquired 1,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.24% of the stock is currently owned by insiders.

Solventum Trading Down 0.2%

Shares of NYSE SOLV opened at $76.08 on Thursday. The company’s fifty day moving average is $69.27 and its 200-day moving average is $75.01. The stock has a market cap of $13.18 billion, a price-to-earnings ratio of 9.32, a P/E/G ratio of 1.18 and a beta of 0.59. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period last year, the firm posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts predict that Solventum Corporation will post 6.57 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on SOLV shares. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. KeyCorp raised their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. UBS Group cut shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Thursday, May 14th. Wedbush assumed coverage on shares of Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective on the stock. Finally, Wells Fargo & Company reduced their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Solventum presently has an average rating of “Moderate Buy” and an average target price of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.